Rozanolixizumab
ATC L04AL02 · 9 markets · 21 records
US 4 records · 1 strengths
- 140 mginjectionRYSTIGGO
CA 4 records · 1 strengths
- 140 mg/1 mLliquidRYSTIGGO
GB 3 records · 3 strengths
- 280 mg/2 mLinjectionRystiggo 280mg/2ml solution for injection vials
- 560 mg/4 mLinjectionRystiggo 280mg/2ml solution for injection vials
- 420 mg/3 mLinjectionRystiggo 280mg/2ml solution for injection vials
AU 3 records · 3 strengths
- 280 mg/2 mLinjectionRYSTIGGO
- 140 mg/mLinjectionRYSTIGGO rozanolixizumab 140 mg/mL solution for injection for infusion vial
1 records · 0 manufacturers 1 registros · 0 fabricantes 1 个记录 · 0 个厂家 1 個記錄 · 0 個廠商
Full list in the data package Lista completa en el paquete de datos 完整清单见数据包 完整清單見資料包
HK 3 records · 1 strengths
3 records · 0 manufacturers 3 registros · 0 fabricantes 3 个记录 · 0 个厂家 3 個記錄 · 0 個廠商
Full list in the data package Lista completa en el paquete de datos 完整清单见数据包 完整清單見資料包
ES 1 records · 1 strengths
- 140 mg/1 mLinjectionRYSTIGGO
TW 1 records · 1 strengths
- 140 mginjectionRystiggo solution for injection 140 mg/ml肌挺力注射液劑140毫克/毫升
EU 1 records · 1 strengths
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
1 records · 0 manufacturers 1 registros · 0 fabricantes 1 个记录 · 0 个厂家 1 個記錄 · 0 個廠商
Full list in the data package Lista completa en el paquete de datos 完整清单见数据包 完整清單見資料包
FR 1 records · 1 strengths
- 140 mg/1 mLinjectionRYSTIGGO 140 mg/mL, solution injectable
| Strength / form / release | US | GB | CA | AU | ES | TW | HK | EU | FR |
|---|---|---|---|---|---|---|---|---|---|
| 140 mg injection | RYSTIGGO | Rystiggo solution for injection 140 mg/ml 肌挺力注射液劑140毫克/毫升 | |||||||
| 280 mg/2 mL injection | Rystiggo 280mg/2ml solution for injection vials | RYSTIGGO | |||||||
| 140 mg/1 mL injection | RYSTIGGO | RYSTIGGO 140 mg/mL, solution injectable | |||||||
| 140 mg/1 mL liquid | RYSTIGGO | ||||||||
| 560 mg/4 mL injection | Rystiggo 280mg/2ml solution for injection vials | ||||||||
| 420 mg/3 mL injection | Rystiggo 280mg/2ml solution for injection vials | ||||||||
| 140 mg/mL injection | RYSTIGGO rozanolixizumab 140 mg/mL solution for injection for infusion vial | ||||||||
unknown | RYSTIGGO | RYSTIGGO SOLUTION FOR INJECTION 280MG/2ML | RYSTIGGO |
Scroll horizontally for more markets →
Each country column shows the locally registered trade names — not translations.
2 more strength/form rows are recorded only in CA · ES · FR and are not shown in this table. Hay 2 filas de concentración/forma registradas solo en CA · ES · FR que no se muestran en esta tabla. 另有 2 个规格/剂型仅在 CA · ES · FR 有记录(未在本表显示)。 另有 2 個規格/劑型僅在 CA · ES · FR 有記錄(未在本表顯示)。
“not disclosed” means the source does not publish the strength — it does not mean the product has none.
Hong Kong records are name/ingredient-level only: no strength, dosage form or registration status; on the register does not prove current supply.
Australia ARTG data has no registration-status column, so status is shown as unknown; being on the register does not mean currently marketed.
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.